STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
• 
• 
• 
• 
For procedures finalised after 1 March 2004 please refer to module 8B. 
On 4 June 1999, the Marketing Authorisation Holder submitted to the EMEA an application for 
a Type I variation related to the extension of the shelf life. The EMEA approved this variation 
on 8 July 1999 which required amendments to Annexes of the Commission Decision. 
On  28  July  1999,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an  application 
for  a  Type  I  variation  related  to  a  change  in  the  qualitative  composition  of  the  immediate 
packaging material (bottles). The EMEA approved on 11 August 1999 this variation which did 
not require any amendments to Annexes of the Commission Decision. 
On  9  November  1999,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application  for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product 
Characteristics  to  reflect  results  from  the  48  weeks  paediatric  study.  The  CPMP,  during  its 
January plenary meeting, considered the changes acceptable, and adopted on 19 January 2000 a 
favourable  opinion  on  the  Type  II  variation.  The  corresponding  Commission  Decision  was 
issued 24 May 2000. 
On  16  July  1999,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an  application 
for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product  Characteristics  and 
Package Leaflet with new data based on 1) reports of genotyping of virus from clinical isolates,  
2)  updated  clinical  study  reports  and  3)  revised  safety  information  resulting  from  increased 
patient  exposure.  The  CPMP,  during  its  September  plenary  meeting,  considered  the  changes 
acceptable, and adopted on 23 September 1999 a favourable opinion on the Type II variation. 
The corresponding Commission Decision was issued on 31 January 2000. 
Medicinal product no longer authorised
On 30 March 2000, the Marketing Authorisation Holder submitted to the EMEA an application 
for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product  Characteristics  and 
Package  Leaflet  in  particular  to  reflect  new  data  on  food  interaction  and  safety  information.  
The CPMP, during its June plenary meeting, considered the changes acceptable, and adopted on 
29  June  2000  a  favourable  opinion  on  the  Type  II  variation.  The  corresponding  Commission 
Decision was issued 13 October 2000. 
Pursuant  to  CPMP  discussion  on  the  potential  of  St  John’s  wort  (Hypericum  perforatum)  to 
interact  with  protease  inhibitors  (PIs)  and  non-nucleoside  reverse  transcriptase  inhibitors 
(NNRTIs), the MAHs for the respective PIs and NNRTIs submitted to the EMEA an application 
for  a  Type  II  variation  to  include  a  class  labelling  wording  in  the  Summary  of  Product 
Characteristics  and  Package  leaflet.  On  29  June  2000,  the  CPMP  adopted  an  Opinion  on  this 
variation and the respective Commission Decision was issued on 13 October 2000. 
On 10 May 2000, the Marketing Authorisation Holder  submitted to the EMEA an application 
for  a  Type  II  variation  related  to  the  introduction  of  an  alternative  route  of  synthesis  of  the 
active  substance.  The  CPMP,  during  its  July  plenary  meeting,  considered  the  changes 
acceptable, and adopted on 27 July 2000 a favourable opinion on the Type II variation, which 
did not require any amendments to the Commission decision.  
On  28  January  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application  for  a  Type  I  variation  related  to  an  extension  of  the  re-test  period  of  the  active 
substance.  The  EMEA  approved  on  2  March  2000  this  variation,  which  did  not  require  any 
amendments to Annexes of the Commission Decision. 
• 
• 
• 
• 
• 
• 
On  24  October  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application for a Type I variation related to a change of the batch size of the active substance. 
The  EMEA  approved  on  24  November  2000  this  variation,  which  did  not  require  any 
amendments to Annexes of the Commission Decision. 
On  30  November  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application  for  a  Type  II  variation  related  to  the  addition  of  an  alternate  manufacturer  of  the 
1/3 
EMEA 2005 
 
 
 
 
 
 
 
 
 
• 
• 
• 
active  substance  and  to  the  redefinition  of  the  starting  material  for  the  synthetic  route  of  the 
active substance. 
The  CPMP,  during  its  February  plenary  meeting,  considered  the  changes  acceptable,  and 
adopted on 1 March 2001 a favourable opinion on the Type II variation, which did not require 
any amendments to the Commission decision.  
On 28 March 2000 The Marketing Authorisation Holder submitted to the EMEA an Annex II 
application  Pursuant  to  Article   2(1)  of  Commission   Regulation   (EC)  No 542/95  of 
10 March 1995, as amended, and Annex  II point 3(iv) The procedure started on 14 April 2000, 
The CPMP, during its June plenary meeting, considered the changes acceptable, and adopted on 
27  June  2001  a  favourable  opinion  on  the  Type  II  variation.  The  corresponding  Commission 
Decision was issued 18 October 2001. 
On  14  February  2001  The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application for a type II variation related the update of the Summary of Product Characteristics 
to  reflect  results  from  indinavir/efavirenz  steady  state  pharmacokinetics  study.  The  procedure 
started  on  2  March  2001.  Supplementary  information  was  supplied  by  the  Marketing 
Authorisation Holder on 4 May 2001. The CPMP, during its May plenary meeting, considered 
the changes acceptable, and adopted on 31 May June 2001 a favourable opinion on the Type II 
variation. The corresponding Commission Decision was issued 20 September 2001. 
On  30  November  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application  for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product 
Characteristics and Package Leaflet following the evaluation of the 2nd Periodic Safety Update 
Report  and  the  availability  of  clinical  data  regarding  the  interaction  between  efavirenz  and 
rifabutin. The CPMP, during its February plenary meeting, considered the changes acceptable, 
and adopted on 1 March 2001 a favourable opinion on the Type II variation. The corresponding 
Commission Decision was issued 14 June 2001. 
Medicinal product no longer authorised
Change  to  demonstrate  compliance  with  Commission  Directive 
1999/82/EC  and  the  Note  for  Guidance  on  Minimising  the  Risk  of 
Transmitting  Animal  Spongiform  Encephalopathy  Agents  via 
Medicinal Products (CPMP/BWP/1230/98 rev.1) 
The  MAH  submitted  to  the  EMEA  on  4 May  2001,  an  Annex  II 
application.  The  existing  numbers  in  the  Community  Register  of 
Medicinal Products for Sustiva, are: EU/1/99/110/001-005 
The  MAH  submitted  to  the  EMEA  on  4 May  2001,  an  Annex  II 
application.  The  existing  numbers  in  the  Community  Register  of 
Medicinal Products for Sustiva, are: EU/1/99/110/001-005 
The  MAH  applied  for  an  update  of  the  Summary  of  Product 
Characteristics  (SPC)  section  4.4  (Special  warnings  and  special 
precautions for use) and section 5.3 (Preclinical safety data).   
Changes to comply with supplements to pharmacopoeias 
Change in container shape 
Change in or addition of manufacturing site(s) for part or all of the 
manufacturing process and consequential change  
Change  in  the  name  and/or  address  of  the  marketing  authorisation 
holder 
Change 
authorisation(s). 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Commission 
Decision 
Issued/amended 
on 
05.05.01 
Notification/ 
Opinion 
issued on2 
21.09.01 
24.10.01 
26.11.01 
23.10.01 
07.01.02 
06.03.02 
Type of 
modification1 
following  modification(s) 
Application 
number 
the  manufacturing 
I/20 
I/21 
I/22 
12.04.02 
30.05.02 
30.05.02 
22.08.02 
22.08.02 
21.03.02 
21.03.02 
31.10.01 
31.10.01 
28.03.01 
13.12.01 
Scope 
X/17 
X/18 
II/19 
I 
I 
I 
I/23 
I/24 
I/16 
of 
X 
X 
II 
I 
I 
I 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation 
(Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure 
set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 
November 1996.  
N refers to a notification in accordance with Article 61(3) of Council Directive 2001/83/EC. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date.  
The Commission Decision will be amended accordingly. 
2/3 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
30.09.02 
I/25 
I 
31.10.01 
06.03.02 
02.04.02 
30.08.02 
07.05.02 
20.06.02 
10.07.02 
04.12.02 
19.05.03 
I 
T 
II 
II 
II 
N 
of 
of 
I/30 
T/28 
II/34 
II/29 
II/27 
N 
N 
N/31 
20.02.03 
27.06.02 
09.04.02 
30.05.02 
28.02.02 
20.06.02 
N/32 
N/33 
14.06.02 
18.11.02 
the  manufacturing 
the  manufacturing 
following  modification(s) 
following  modification(s) 
Change 
authorisation(s) 
The  MAH  applied  for  an  update  of  the  SPC  sections  4.3,  4.4,  4.5 
and  4.8  and  corresponding  sections  of  the  Package  leaflet  (PL).  
The application is based on newly completed interaction studies and 
on  two  adverse  events  reported  in  the  4th  efavirenz  PSUR.  
In  addition,  a  class  wording  on  St-John’s  Wort  is  added,  as  agreed 
with CPMP. 
Bristol-Myers Squibb Pharma (UK) Limited submitted to the EMEA 
on 21 January 2002 an application for the transfer of the Marketing 
Authorisation to Bristol-Myers Squibb Pharma EEIG 
Update  of  the  SPC  for  the  oral  solution  in  order  to  include 
information on  the final results  of study  DMP266-111, “A Phase I, 
Open-label, Single-dose, Randomized; Two-period Crossover Study 
in  Healthy  Volunteers  to  Determine  the  Effect  of  Food  on  the 
Bioavailability of Efavirenz Oral Solution. 
Change 
authorisation(s) 
Changes to the PL local representatives address for France, Finland 
and  Ireland.  The  phone  numbers  for  the  local  representatives  in 
Greece  and  Germany  are  modified.  Local  representatives  for 
Belgium,  Luxembourg,  Ireland  and  UK  are  listed  individually  in 
accordance with the latest QRD template. 
Changes of the local representative name in Italy. 
Changes  of  the  local  representative  names  in  Italy  and  Spain.  The 
phone number for the local representative in Ireland is modified. 
To amend sections 4.4 and 4.8 of the SPC as requested by the CPMP 
on  July  2002,  following  the  assessment  of  PSUR  5,  in  order  to 
adequately  reflect  the  safety  concerns  with  regard  to  suicide.  In 
particular, 
the  Marketing  Authorisation  Holder  (MAH)  was 
requested to delete “occasional” in sections 4.4 and 4.8 and “a causal 
relationship to the use of efavirenz cannot be determined from these 
reports” in sections 4.8. 
Moreover, the MAH took this opportunity to update the SPC and the 
PL  of  the  300mg  and  the  600mg  film-coated  tablet  presentations, 
following  variation  II/27  for  Sustiva,  adopted  at  the  June  2002 
CPMP for the hard capsules and the oral solution presentation. 
The  MAH  applied  for  an  update  of  the  SPC  to  include  the  class 
labelling on Lipodystrophy in sections 4.4 and 4.8. Relevant changes 
are equally proposed for the Package Leaflet. 
Extension of shelf-life as foreseen at time of authorisation. 
Minor changes in manufacture of the medicinal productChange in or 
addition of manufacturing site(s) for part or all of the manufacturing 
process 
Update  of  section  4.4  (Special  warnings  and  special  precautions  of 
use) and 5.2 (Pharmacokinetic properties) of the SPC to implement 
the class labelling on liver impairment adopted by the CPMP for all 
anti-retroviral  medicinal  products  on  25  April  2003.  Furthermore, 
the  MAH  has  taken  this  opportunity  to  update  section  4.4  of  the 
SPC, by reordering the wording on lactose (for the 300 and 600 mg 
tablet  formulations  only),  on  cholesterol  and  on  lipodystrophy.  In 
addition,  the  MAH  has  proposed  to  update  the  PL  in  line  with  the 
proposed  changes  of  the  SPC  and  to  include  the  wording  on 
on 
lipodystrophy 
24 March 2003. 
Addition or replacement of measuring device for oral liquid dosage 
forms and other dosage forms 
Replacement/add. of manufacturing site: Secondary packaging site 
Deletion of manufacturing site 
Deletion of manufacturing site 
Replacement/add.  of  manufacturing  site:  Primary  packaging  site  - 
Solid forms 
 Medicinal product no longer authorised
17.11.03 
27.01.04 
30.01.04 
IA/42 
IA/44 
IA/45 
08.05.03 
07.07.03 
IA 
IA 
IA 
I/36 
I/37 
16.10.03 
20.11.03 
19.03.03 
adopted 
CPMP 
II/35 
II/38 
- 
- 
- 
I/39 
the 
I 
I 
by 
as 
II 
II 
I 
09.07.03 
25.06.03 
22.07.03 
05.02.04 
23.10.03 
3/3 
EMEA 2005 
 
 
 
 
 
 
 
